About Abgenics Life Sciences
Abgenics Life Sciences is a company based in Pune (India) founded in 2010 by Anil Nahar. Abgenics Life Sciences offers products and services including AbTids®, Lactobacillus mediated delivery, Antibody Libraries, and CaMab-Drug Combinations. Abgenics Life Sciences operates in a competitive market with competitors including Novozymes, Azitra, Seed, Seres Therapeutics and MaaT Pharma, among others.
- Headquarter Pune, India
- Founders Anil Nahar
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Abgenics Life Sciences Private Limited
- Date of Incorporation 01 Jun, 2010
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$33.19 K (USD)130.6as on Mar 31, 2020
-
Net Profit
-$74.11 K (USD)45.05as on Mar 31, 2020
-
EBITDA
-$74.53 K (USD)43.5as on Mar 31, 2020
-
Latest Funding Round
$100 K (USD), Grant
Feb 14, 2014
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abgenics Life Sciences
Abgenics Life Sciences offers a comprehensive portfolio of products and services, including AbTids®, Lactobacillus mediated delivery, Antibody Libraries, and CaMab-Drug Combinations.
Fuses camelid antibodies with antimicrobial peptides for anti-infectives.
Delivers RNAi via Lactobacillus for targeted therapeutic applications.
Provides libraries of antibodies for research and disease detection.
Combines camelid antibodies with drugs for enhanced anti-cancer treatments.
Funding Insights of Abgenics Life Sciences
Investors in Abgenics Life Sciences
Abgenics Life Sciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Abgenics Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abgenics Life Sciences
Investment portfolio details for Abgenics Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Abgenics Life Sciences
Detailed financials for Abgenics Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abgenics Life Sciences Comparisons
Peer comparison for Abgenics Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abgenics Life Sciences
Abgenics Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novozymes, Azitra, Seed, Seres Therapeutics and MaaT Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| Locked | Locked | Locked |
Microbiome-based therapeutics for skin conditions like eczema are developed.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Microbiome therapeutics are developed to address diverse diseases.
|
|
| Locked | Locked | Locked |
Microbiome therapies are developed for treating intestinal dysbiosis diseases.
|
|
| Locked | Locked | Locked |
Microbiome-based immuno-oncology drugs are developed using proprietary technology.
|
Detailed competitors of Abgenics Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abgenics Life Sciences
Complete news archive for Abgenics Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abgenics Life Sciences
Abgenics Life Sciences was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Abgenics Life Sciences is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Annual revenue of Abgenics Life Sciences is $33.19K as on Mar 31, 2020.
Abgenics Life Sciences was founded in 2010 in Pune, India, within the biotechnology sector. Focus is placed on creating therapeutic agents for helminth infections through probiotic strains of Lactobacillus. These strains are engineered to reside in the human gut and generate RNA molecules that target and disrupt specific parasite genes, leading to infection clearance. The approach is designed for sustained management of various worm infections.
Abgenics Life Sciences's top competitors include Novozymes, Azitra and Seres Therapeutics.
Abgenics Life Sciences offers AbTids®, Lactobacillus mediated delivery, Antibody Libraries, and CaMab-Drug Combinations.
Abgenics Life Sciences has 1 investor. Key investors include Gates Foundation.